Federated Hermes, Inc. Annexon, Inc. Transaction History

Federated Hermes, Inc.

$43.6 Billion
Q3 2024

A detailed history of Federated Hermes, Inc. transactions in Annexon, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 4,924 shares of ANNX stock, worth $25,260. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,924

Previous 2,882 70.85%

Holding current value

$25,260

Previous $14,000 107.14%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$4.49 - $7.2 $9,168 - $14,702	2,042 Added 70.85%	4,924 $29,000
Q2 2024 Aug 08, 2024	BUY	$4.33 - $6.79 $6,923 - $10,857	1,599 Added 124.63%	2,882 $14,000
Q1 2024 May 14, 2024	BUY	$4.03 - $7.81 $5,170 - $10,020	1,283 New	1,283 $9,000
Q3 2023 Nov 13, 2023	SELL	$2.13 - $3.84 $5.48 Million - $9.88 Million	-2,572,753 Reduced 84.14%	485,047 $1.14 Million
Q3 2022 Nov 14, 2022	BUY	$3.75 - $6.63 $18,150 - $32,089	4,840 Added 0.16%	3,057,800 $18.9 Million
Q2 2022 Aug 15, 2022	BUY	$2.11 - $4.06 $651 - $1,254	309 Added 0.01%	3,052,960 $11.5 Million
Q1 2022 May 13, 2022	BUY	$2.73 - $11.94 $2.8 Million - $12.3 Million	1,027,051 Added 50.7%	3,052,651 $8.33 Million
Q4 2021 Feb 14, 2022	SELL	$11.49 - $22.0 $24,129 - $46,200	-2,100 Reduced 0.1%	2,025,600 $23.3 Million
Q3 2021 Nov 15, 2021	BUY	$16.35 - $23.4 $441,450 - $631,800	27,000 Added 1.35%	2,027,700 $37.7 Million
Q1 2021 May 13, 2021	BUY	$22.0 - $35.01 $12.4 Million - $19.7 Million	563,700 Added 39.23%	2,000,700 $55.7 Million
Q4 2020 Feb 12, 2021	BUY	$20.81 - $30.55 $2.06 Million - $3.02 Million	98,825 Added 7.39%	1,437,000 $36 Million
Q3 2020 Nov 12, 2020	BUY	$17.5 - $30.23 $23.4 Million - $40.5 Million	1,338,175 New	1,338,175 $40.5 Million

Others Institutions Holding ANNX

# of Institutions

146

Shares Held

102M

Call Options Held

178K

Put Options Held

159K

View Full List

About Annexon, Inc.

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $244M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

More about ANNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account

Federated Hermes, Inc. Annexon, Inc. Transaction History